Alberto Sobrero
阿尔贝托·索布雷罗
MD
Director, Medical Oncology Unit; Professor of Oncology, University of Genoa肿瘤内科主任；热那亚大学肿瘤学教授
👥Biography 个人简介
Alberto Sobrero is a veteran Italian medical oncologist whose career has profoundly shaped chemotherapy and targeted therapy strategies in metastatic colorectal cancer. He was co-principal investigator of the EPIC trial establishing irinotecan plus cetuximab activity in second-line mCRC, and has led several GONO consortium trials optimizing FOLFOX and FOLFIRI duration and sequencing. His work on intermittent chemotherapy schedules and maintenance strategies has been influential in reducing cumulative toxicity without compromising efficacy in patients receiving long-term treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
EPIC Trial — Cetuximab in Second-Line mCRC
Co-led the EPIC phase III trial demonstrating that adding cetuximab to irinotecan in KRAS-wildtype second-line mCRC improved progression-free survival and response rate, contributing to the expanded indication of cetuximab across treatment lines.
GONO FOLFOXIRI Triplet Chemotherapy
Collaborated with the GONO group on landmark trials establishing FOLFOXIRI (5-FU, oxaliplatin, irinotecan) plus bevacizumab as a high-efficacy first-line option in fit mCRC patients, demonstrating superior response and resection rates versus FOLFIRI plus bevacizumab (TRIBE trial).
Intermittent Chemotherapy and Maintenance Strategies
Conducted key randomized studies exploring planned chemotherapy interruptions and maintenance therapy (e.g., capecitabine plus bevacizumab) in mCRC, balancing quality of life with disease control and informing contemporary maintenance treatment paradigms.
Representative Works 代表性著作
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated fluorouracil, leucovorin, and irinotecan with cetuximab results
Journal of Clinical Oncology (2012)
Updated CRYSTAL trial results confirming durable overall survival benefit of cetuximab plus FOLFIRI in KRAS-wildtype first-line mCRC.
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer (TRIBE): a randomised, open-label, phase 3 trial
The Lancet (2014)
Landmark TRIBE trial demonstrating superior PFS and OS with FOLFOXIRI/bevacizumab triplet over FOLFIRI/bevacizumab doublet in first-line unselected mCRC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 阿尔贝托·索布雷罗 的研究动态
Follow Alberto Sobrero's research updates
留下邮箱，当我们发布与 Alberto Sobrero（IRCCS Ospedale Policlinico San Martino, Genoa）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment